Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II-III trial of ALK HDM tablet doses in house dust mite allergic subjects
2006-001795-20Phase 2Completed
- Sponsor
- ALK-Abelló
- Start
- May 2006
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of House dust mite allergen extract in asthma and allergic rhinitis (AR) (4 arms), sponsored by ALK-Abelló. Primary endpoint: Reduction in inhaled corticosteroid dosage from baseline to first year of treatment. Started May 2006; status: completed.
02
Drugs
House dust mite allergen extract
03
Conditions
asthmaallergic rhinitis (AR)
Beyond the preview
Go deeper on 2006-001795-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001795-20.